Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Abstract Introduction Drotrecogin alfa (activated; recombinant activated protein C) was shown to reduce 28-day all-cause mortality in patients with severe sepsis and to have an acceptable safety profile in 1690 patients studied in the F1K-MC-EVAD (PROWESS) trial. We analyzed all available data on th...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Revisão |
| Jazyk: | angličtina |
| Vydáno: |
2003
|
| On-line přístup: | https://doi.org/10.1186/cc2167 https://ccforum.biomedcentral.com/counter/pdf/10.1186/cc2167 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|